Botulinum Toxin Type A Injection to Prevent Keloid Recurrence
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The prospective, split-scar, double-blind, randomized controlled study will enroll the
patients who are older than 20 years with progressive keloid lesion which is symmetric.
Botulinum toxin A will be injected into half of each keloid revision wound immediately after
skin closure. The scars will be assessed at 1-year follow-up with Vancouver Scar Scale (VSS),
Patient and Observer Scar Assessment Scale (POSAS), and the Cutometer.
Phase:
Phase 4
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
Tainan Hospital, Ministry of Health and Welfare
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A